- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Zydus Lifesciences secured final USFDA approval for Bosentan tablets (32 mg) for pediatric PAH treatment. This targets a US market with annual sales of approximately USD 9.3 million, strengthening its US product portfolio.